ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV - Seite 4

Drug Interactions: Co-administration of Tivicay with certain
inducers of UGT1A and/or CYP3A may reduce plasma concentrations of
dolutegravir and require dose adjustments of Tivicay. Administer
Tivicay 2 hours before or 6 hours after taking polyvalent
cation-containing antacids or laxatives, sucralfate, oral supplements
containing iron or calcium, or buffered medications. Alternatively,
Tivicay and supplements containing calcium or iron can be taken with
food. Consult the full Prescribing Information for Tivicay for more
information on potentially significant drug interactions, including
clinical comments.

Pregnancy Category B: Tivicay should be used during pregnancy only
if the potential benefit justifies the potential risk. An
Antiretroviral Pregnancy Registry has been established.

Nursing Mothers: Breastfeeding is not recommended due to the
potential for HIV transmission and the potential for adverse
reactions in nursing infants.

Paediatric Patients: Safety and efficacy of Tivicay have not been
established in paediatric patients weighing less than 30kg or in any
paediatric patients who are INSTI-experienced.

Full US Prescribing Information for Tivicay is available at: https
://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescri
bing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF

About the Medicines Patent Pool

The Medicines Patent Pool (MPP) is a United Nations-backed public
health organisation working to increase access to HIV, viral
hepatitis C and tuberculosis treatments in low- and middle-income
countries. Through its innovative business model, the MPP partners
with industry, civil society, international organisations, patient
groups and other stakeholders to prioritise, forecast and license
needed medicines and pool intellectual property to encourage generic
manufacture and the development of new formulations. To date, the MPP
has signed agreements with six patent holders for twelve HIV
antiretrovirals and for one hepatitis C direct-acting antiviral. Its
generic partners have distributed more than three billion doses of
low-cost medicines to 117 countries. The MPP was founded and remains
fully funded by UNITAID.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in
November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE)
dedicated to delivering advances in treatment and care for people
living with HIV. Shionogi (TYO: 4507) joined in October 2012. The
company's aim is to take a deeper and broader interest in HIV/AIDS